港股異動 | 和黃醫藥漲超7% 啟動治療晚期乳癌或子宮內膜患者臨牀試驗
格隆匯9月1日丨和黃醫藥(0013.HK)上漲7.3%至62.9港元,總市值為543億港元;昨晚美股和黃醫藥(HCM.US)最高漲至6.67%,報價40.67美元。和黃醫藥8月26日發佈公吿稱,在美國啟動了一項呋喹替尼(fruquintinib)聯合百濟神州(6160.HK)的替雷利珠單抗(tislelizumab)治療晚期三陰性乳線癌或晚期子宮內膜癌患者的Ib/II期臨牀試驗。首名受試者已於今年8月24日接受該藥治療。而早在8月23日,和黃醫藥發佈公吿,和黃醫藥獲納入包括恆生綜合指數在內的數項由恆生管理的指數,包括恆生醫療保健指數及恆生香港上市生物科技指數等其他六項香港上市股票指數,並將於2021年9月6日正式生效。除上述香港上市股票指數外,恆生還將和黃醫藥納入六項跨市場指數,其中包括恆生滬深港通中國500指數。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.